Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 ... CTI’ new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous ... control device that will increase healthcare worker safety and reduce financial costs. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students ... part in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught ... summer 2014, this course combines students from both universities and is taught on ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... 2 Neogen Corporation (Nasdaq: NEOG ) announced ... agreement with the Chinese government to research China-specific food safety ... created a jointly funded laboratory in Beijing. Testing methods and ... than 30 other labs throughout China. , , "This ...
... ... adaptive trial experts offering practical guidelines for designing and implementing adaptive ... planning challenges often remain overlooked in the clinical development process. ... ranging from understanding the potential for changes in resource allocations to ...
... cost-effective, Genomatica looks to develop demonstration plant , ... a sustainable chemicals company, announced today that the ... toward the production of commercial grade 1,4-butanediol (BDO) ... The company has demonstrated that it can process ...
Cached Biology Technology:Neogen Partners With Chinese Government 2ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials" 2ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials" 3Genomatica Produces Pure BDO From Natural Sugars 2Genomatica Produces Pure BDO From Natural Sugars 3Genomatica Produces Pure BDO From Natural Sugars 4
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... , June 16, 2015 ... Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies ... Forecast to 2020" published by MarketsandMarkets, The Natural Language ... at a CAGR of 18.4% for the forecast period ... and   46 F igures spread   through ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... collaborative research team led by Professor Tadashi ISA, ... Institute for Physiological Sciences, The National Institutes of ... University, developed "the double viral vector transfection technique" ... circuit by combining two new kinds of gene ...
... Olympic Committee (IOC) Medical and Scientific Department has recognized ... as an international leader in researching and preventing sports ... the Faculty of Kinesiology, will be named one of ... at a special reception to be held on June ...
... glimpse of climate change beyond images of melting ... like the coastal Caribbean, mountainous eastern Australia, and ... related impacts. ,Co-edited by Drs. Jodi Hilty ... Charles Chester of Tufts and Brandeis Universities, the ...
Cached Biology News:Manipulation of a specific neural circuit buried in complicated brain networks in primates 2IOC recognizes University of Calgary Sports Injury Research Prevention Centre 2As world warms, conservation evolves 2
...
Applications: Western blotting ...
...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
Biology Products: